Sample Size Based on Pharmacodynamic endpoints [Power / Sample Size]

posted by ElMaestro  – Belgium?, 2019-04-03 13:22 (571 d 02:28 ago) – Posting: # 20118
Views: 2,320

Hi sury,

» Can anyone have any idea how can we provide sample size for the PD endpopints

The overarching principle is the same:
You need to guesstimate the resemblance along with the variability of the quantity on which equivalence is determined. The first one is entirely formulation dependent, the latter is biological in nature.
In consequence you first decide on the design and the stats model, and then you work out the sample size from that model.

You will need to be very, very specific in order for anyone here to help you with the actual sample size. Very often you will not find info in the public domain that can be used to calculate sample size (like variability for certain nasal and inhalation drug PD endpoints). In those cases where you can't look up variability in literature/FOI act access/journals/etc you will not get a qualified sample size without at least a pilot study.
Note also that for FDA some PD endpoints are complex in that superiority to placebo is required along with proof of equivalence for T vs R. This is not always entirely straightforward.

I could be wrong, but...

Best regards,
ElMaestro

No, of course you do not need to audit your CRO if it was inspected in 1968 by the agency of Crabongostan.

Complete thread:

Activity
 Admin contact
21,179 posts in 4,414 threads, 1,474 registered users;
online 5 (0 registered, 5 guests [including 3 identified bots]).
Forum time: Sunday 14:50 CET (Europe/Vienna)

Mediocrity knows nothing higher than itself,
but talent instantly recognizes genius.    Arthur Conan Doyle

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5